NCT04231864 - Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | Biotech Hunter

Timeline

Start Date

December 1, 2020

Primary Completion Date

April 1, 2022

Study Completion Date

April 1, 2024

Conditions

Epstein-Barr Virus PositiveMetastatic Nasopharyngeal CarcinomaRecurrent Nasopharyngeal CarcinomaStage III Nasopharyngeal CarcinomaStage IV Nasopharyngeal CarcinomaStage IVA Nasopharyngeal CarcinomaStage IVB Nasopharyngeal Carcinoma

Interventions

BIOLOGICAL

Durvalumab

Given intravenously (IV)

DRUG

Epacadostat

Given orally (PO)